Anuh Pharma
77.59
-0.67(-0.86%)
Market Cap₹777.64 Cr
PE Ratio18.82
IndustryHealthcare
Company Performance:
1D-0.86%
1M-5.08%
6M-11.98%
1Y+0.65%
5Y-30.37%
View Company Insightsright
More news about Anuh Pharma
26Aug 25
Anuh Pharma Shareholders Approve Key Leadership Appointments and Auditor Reappointments at 65th AGM
Anuh Pharma Limited held its 65th Annual General Meeting on August 22, 2025. Shareholders approved reappointments of Non-Executive Directors Bharat Nemchand Shah and Gaurav Satish Shah, and Joint Managing Directors Ritesh Shah and Vivek Shah for a five-year term. Mr. Ankit Kishor Chande was reappointed as Cost Auditor, and M/s. GHV & Co. as Secretarial Auditor for five years. All resolutions received over 99.99% votes in favor. A dividend of Rs. 1.50 per equity share was declared for FY 2024-25.
 no imag found
08Aug 25
Anuh Pharma Reports Q1 Revenue Growth, Appoints New Chief Marketing Officer
Anuh Pharma Limited announced Q1 financial results with revenue from operations increasing by 35.2% year-over-year to Rs 18,647.94 lakhs. However, profit after tax decreased slightly to Rs 830.12 lakhs. The company's EBITDA margin declined to 7.34% from 10.36% in the previous year. Additionally, Anuh Pharma appointed Mr. Vinayak Shenoy as Chief Marketing Officer, effective August 11, 2025, bringing over 15 years of experience in APIs and Intermediates across global markets.
 no imag found
15Jul 25
Anuh Pharma Boosts Production Capacity with New Manufacturing Facility in Tarapur
Anuh Pharma Limited has inaugurated a new manufacturing facility, Manufacturing Block INT-1A, in Tarapur, Maharashtra. The facility, opened on July 15, 2025, will increase the company's production capacity by 200 MT/Annum, bringing the total to approximately 2,400 MT/Annum. The expansion includes an additional 40 KL of reactor capacity, enhancing the company's infrastructure to meet growing market demands in the pharmaceutical sector.
 no imag found
23May 25
Anuh Pharma Reports Mixed Q4 Results, Recommends Dividend
Anuh Pharma Ltd. released its Q4 FY2023-24 results, showing a 15.85% increase in revenue to ₹1,900 crore. However, net profit declined by 18.62% to ₹125 crore. The company's EBITDA margin contracted to 10.48%. Despite Q4 challenges, annual performance for FY2024 was strong with a 23.52% revenue growth and 66.02% increase in net profit. The board recommended a dividend of ₹1.50 per equity share.
 no imag found
Anuh Pharma
77.59
-0.67
(-0.86%)
1 Year Returns:+0.65%
Industry Peers
Sun Pharmaceutical
1,801.60
(-1.30%)
Divis Laboratories
6,071.00
(-3.36%)
Torrent Pharmaceuticals
4,390.00
(-1.26%)
Dr Reddys Laboratories
1,292.30
(-2.02%)
Cipla
1,314.70
(-0.72%)
Lupin
2,314.90
(-1.80%)
Zydus Life Science
905.90
(-1.20%)
Mankind Pharma
2,138.90
(-3.13%)
Aurobindo Pharma
1,296.50
(-1.17%)
Alkem Laboratories
5,355.50
(-1.63%)